Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Grifols S.A. (GRFS)

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,229,321
  • Shares Outstanding, K 687,554
  • Annual Sales, $ 5,299 M
  • Annual Income, $ 704,630 K
  • 60-Month Beta 1.16
  • Price/Sales 2.87
  • Price/Cash Flow 14.18
  • Price/Book 2.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.33
  • Number of Estimates 2
  • High Estimate 0.34
  • Low Estimate 0.31
  • Prior Year 0.34
  • Growth Rate Est. (year over year) -2.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.60 +12.86%
on 06/26/19
22.50 -1.69%
on 07/18/19
+2.45 (+12.46%)
since 06/19/19
3-Month
17.57 +25.90%
on 05/31/19
22.50 -1.69%
on 07/18/19
+3.46 (+18.54%)
since 04/18/19
52-Week
17.42 +26.98%
on 12/24/18
22.50 -1.69%
on 07/18/19
+1.22 (+5.84%)
since 07/19/18

Most Recent Stories

More News
Grifols presents additional encouraging Alzheimer's trial results at AAIC

The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
Company News for Jul 8, 2019

Companies In The News Are: OASM,GOL,GRFS,DELL

GOL : 20.48 (-1.77%)
OASM : 2.01 (+0.50%)
GRFS : 22.12 (-0.14%)
DELL : 56.80 (-1.03%)
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S....

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
Grifols Selected to Build Its First Intravenous Solutions Manufacturing Line in Africa

Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced it has been selected by Soludia Maghreb,...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
GRFS or ORINY: Which Is the Better Value Stock Right Now?

GRFS vs. ORINY: Which Stock Is the Better Value Option?

GRFS : 22.12 (-0.14%)
ORINY : 18.7400 (-1.26%)
Grifols Announces the Opening of its new Plasma Donor Center in Hinesville, Georgia

Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 108 West Hendry Street, Hinesville, Georgia. The 11,000 square foot state-of-the-art facility officially opened...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
Grifols donations of blood clotting factor helping people with hemophilia globally

Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
Immunoglobulins Market to Touch US$ 20,757.1 Mn by 2026, Advancements in Research and Development of Plasma Synthesis to Boost Prospects - TMR

Transparency Market Research (TMR) points entry of new players in the global immunoglobulins market. This is due to a significant boost in number of FDA approvals for immunoglobulins drugs and vaccinations....

GRFS : 22.12 (-0.14%)
New Research: Key Drivers of Growth for Grifols, S.A, LG Display Co., Summit Midstream Partners, LP, Mammoth Energy Services, Reading International, and Great Ajax -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Grifols, S.A. (NASDAQ:GRFS),...

RDI : 13.01 (+0.15%)
SMLP : 7.36 (+0.68%)
GRFS : 22.12 (-0.14%)
LPL : 7.17 (unch)
RDIB : 22.56 (-13.23%)
TUSK : 6.41 (-1.08%)
AJX : 13.62 (+0.29%)
Grifols 2018 Annual Report on Form 20-F Filed With the SEC on April 5, 2019

Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade GRFS with:

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Key Turning Points

2nd Resistance Point 22.38
1st Resistance Point 22.25
Last Price 22.12
1st Support Level 21.98
2nd Support Level 21.83

See More

52-Week High 22.50
Last Price 22.12
Fibonacci 61.8% 20.56
Fibonacci 50% 19.96
Fibonacci 38.2% 19.36
52-Week Low 17.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar